Newron Pharmaceuticals Spa

Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program

Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia

EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan

Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent

Newron to Host Investor and Partnering Meetings During the J.P. Morgan Healthcare Conference Week